NASDAQ:VAXX Vaxxinity - VAXX Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Vaxxinity, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $3.58 +0.53 (+17.38%) (As of 01/27/2023 12:00 AM ET) Add Compare Share Share Today's Range$2.94▼$3.6250-Day Range$1.31▼$3.5852-Week Range$1.24▼$8.35Volume542,347 shsAverage Volume501,595 shsMarket Capitalization$451.29 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Vaxxinity MarketRank™ ForecastAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy2.57% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.02Based on 3 Articles This WeekInsider TradingSelling Shares$2.16 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($0.60) to ($0.63) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.36 out of 5 starsMedical Sector1009th out of 1,055 stocksPharmaceutical Preparations Industry492nd out of 519 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Vaxxinity. Previous Next 4.0 Short Interest Percentage of Shares Shorted2.57% of the float of Vaxxinity has been sold short.Short Interest Ratio / Days to CoverVaxxinity has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Vaxxinity has recently decreased by 4.52%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldVaxxinity does not currently pay a dividend.Dividend GrowthVaxxinity does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VAXX. Previous Next 1.7 News and Social Media Coverage News SentimentVaxxinity has a news sentiment score of -0.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Vaxxinity this week, compared to 1 article on an average week.Search Interest6 people have searched for VAXX on MarketBeat in the last 30 days. This is an increase of 20% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Vaxxinity to their MarketBeat watchlist in the last 30 days. This is a decrease of -80% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Vaxxinity insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,162,240.00 in company stock.Percentage Held by Insiders64.39% of the stock of Vaxxinity is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 20.84% of the stock of Vaxxinity is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Vaxxinity are expected to decrease in the coming year, from ($0.60) to ($0.63) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vaxxinity is -2.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vaxxinity is -2.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVaxxinity has a P/B Ratio of 3.48. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Vaxxinity (NASDAQ:VAXX) StockVaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease (AD) that is in phase 2 clinical trial; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy that is in phase 1 clinical trial; and an anti-tau product candidate for various neurodegenerative conditions, including AD. It is also developing UB-313 that targets calcitonin gene-related peptide to fight migraines; anti-PCSK9 that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; and UB-612 for neutralizing the SARS-CoV-2 virus, which is in phase 3 clinical trial. Vaxxinity, Inc. was founded in 2014 and is headquartered in Dallas, Texas.Read More Receive VAXX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vaxxinity and its competitors with MarketBeat's FREE daily newsletter. Email Address VAXX Stock News HeadlinesJanuary 28, 2023 | americanbankingnews.comVaxxinity, Inc. (NASDAQ:VAXX) Major Shareholder Sells $1,357,476.95 in StockJanuary 19, 2023 | finance.yahoo.comWhy Shares of Vaxxinity Jumped This WeekJanuary 28, 2023 | Porter & Company (Ad)The Next Big Crisis Is HereYou just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.January 5, 2023 | finance.yahoo.comVaxxinity to Present at the 2023 J.P. Morgan Healthcare ConferenceDecember 31, 2022 | finance.yahoo.comEstimating The Fair Value Of Vaxxinity, Inc. (NASDAQ:VAXX)December 2, 2022 | finance.yahoo.comVaxxinity Announces Positive Topline Pivotal Phase 3 COVID-19 Booster Data for UB-612November 10, 2022 | finance.yahoo.comVaxxinity Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateNovember 3, 2022 | finance.yahoo.comVaxxinity to Host First Analyst and R&D Day in New York City on November 10, 2022January 28, 2023 | Porter & Company (Ad)Is This The End of Capitalism?EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…November 1, 2022 | finance.yahoo.comVaxxinity to Present at Upcoming Investor Conferences in NovemberOctober 30, 2022 | finance.yahoo.comVaxxinity, Inc. (NASDAQ:VAXX) stock most popular amongst private companies who own 48%, while individual investors hold 21%October 24, 2022 | finance.yahoo.comVaxxinity Completes Enrollment in Pivotal Phase 3 Clinical Trial of UB-612 COVID-19 Vaccine Heterologous Booster Candidate and Initiates Rolling Submission for Provisional Approval in AustraliaOctober 11, 2022 | uk.finance.yahoo.comVaxxinity, Inc. (VAXX)September 21, 2022 | finance.yahoo.comImmunis Welcomes Dr. Peter Diamandis to the Executive Advisory Board - Yahoo FinanceSeptember 19, 2022 | finance.yahoo.comMultiple insiders bought Vaxxinity, Inc. (NASDAQ:VAXX) stock earlier this year, a positive sign for shareholdersSeptember 13, 2022 | globenewswire.comVaxxinity Announces First Subjects Dosed in Phase 1 Clinical Trial of UB-313 for Preventive Treatment of Migraine - GlobeNewswireSeptember 13, 2022 | finance.yahoo.comVaxxinity Announces First Subjects Dosed in Phase 1 Clinical Trial of UB-313 for Preventive Treatment of MigraineSeptember 12, 2022 | globenewswire.comVaxxinity Initiates Rolling Submission for UB-612 COVID-19 Vaccine with MHRA (UK) - GlobeNewswireSeptember 12, 2022 | finance.yahoo.comVaxxinity Initiates Rolling Submission for UB-612 COVID-19 Vaccine with MHRA (UK)September 1, 2022 | globenewswire.comVaxxinity to Present at Upcoming Investor Conferences in September - GlobeNewswireSeptember 1, 2022 | finance.yahoo.comVaxxinity to Present at Upcoming Investor Conferences in SeptemberAugust 29, 2022 | bizjournals.comCureVac is back in the Covid-19 vaccine game, this time with 'lessons learned' - Boston Business Journal - The Business JournalsAugust 12, 2022 | finance.yahoo.comVaxxinity CEO on COVID: The market isn't going away and it's going to be a massive commercial opportunity - Yahoo FinanceAugust 12, 2022 | finance.yahoo.comVaxxinity CEO on COVID: The market isn't going away and it's going to be a massive commercial opportunityAugust 12, 2022 | finance.yahoo.comVaxxinity Reports Second Quarter 2022 Financial Results and Provides Corporate Updates - Yahoo FinanceAugust 11, 2022 | seekingalpha.comVaxxinity GAAP EPS of -$0.14 beats by $0.24 (NASDAQ:VAXX) - Seeking AlphaAugust 11, 2022 | globenewswire.comVaxxinity Reports Second Quarter 2022 Financial Results and Provides Corporate Updates - GlobeNewswireSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive VAXX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vaxxinity and its competitors with MarketBeat's FREE daily newsletter. Email Address VAXX Company Calendar Last Earnings11/10/2022Today1/28/2023Next Earnings (Estimated)3/23/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:VAXX CUSIPN/A CIK1851657 Webwww.vaxxinity.com Phone254-244-5739FaxN/AEmployees89Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.24) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-137,180,000.00 Net MarginsN/A Pretax Margin-603,670.63% Return on Equity-100.72% Return on Assets-73.48% Debt Debt-to-Equity Ratio0.12 Current Ratio3.33 Quick Ratio3.33 Sales & Book Value Annual Sales$70,000.00 Price / Sales6,447.07 Cash FlowN/A Price / Cash FlowN/A Book Value$1.03 per share Price / Book3.48Miscellaneous Outstanding Shares126,060,000Free Float44,889,000Market Cap$451.29 million OptionableNot Optionable Beta0.55 Key ExecutivesMr. Louis Garfield Reese IV (Age 39)Co-Founder & Exec. Chairman Comp: $428.03kMs. Mei Mei Hu J.D. (Age 38)CEO & Director Comp: $428.03kDr. Ulo Palm M.D. (Age 65)Ph.D., Chief Medical Officer Comp: $551.19kMr. Jason Pesile CPA (Age 49)M.B.A., Sr. VP of Fin. & Accounting Mr. Dwayne SoissonVP of OperationsMr. Benjamin MatoneVP of Investor RelationsMr. Rene Paula Molina (Age 43)Gen. Counsel & Sec. Mr. Jon HarrisonChief Gov. OfficerMr. Mark JoinnidesChief of StaffMs. Amy B. Fix M.B.A.M.S., R.A.C., Chief Regulatory OfficerMore ExecutivesKey CompetitorsAdicet BioNASDAQ:ACETWave Life SciencesNASDAQ:WVEConcert PharmaceuticalsNASDAQ:CNCEALX OncologyNASDAQ:ALXOPepGenNASDAQ:PEPGView All CompetitorsInsiders & InstitutionsMovers Lab Fund I Lp PrimeSold 405,217 sharesTotal: $1.36 M ($3.35/share)Movers Lab Fund I Lp PrimeSold 270,964 sharesTotal: $804,763.08 ($2.97/share)Prime Movers Lab LLCSold 245,038 shares on 11/15/2022Ownership: 13.968%Vanguard Group Inc.Bought 681,666 shares on 11/15/2022Ownership: 1.755%BlackRock Inc.Bought 373,261 shares on 11/15/2022Ownership: 0.296%View All Insider TransactionsView All Institutional Transactions VAXX Stock - Frequently Asked Questions Should I buy or sell Vaxxinity stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Vaxxinity in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" VAXX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in VAXX, but not buy additional shares or sell existing shares. View VAXX analyst ratings or view top-rated stocks. How have VAXX shares performed in 2023? Vaxxinity's stock was trading at $1.40 on January 1st, 2023. Since then, VAXX stock has increased by 155.7% and is now trading at $3.58. View the best growth stocks for 2023 here. When is Vaxxinity's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 23rd 2023. View our VAXX earnings forecast. How were Vaxxinity's earnings last quarter? Vaxxinity, Inc. (NASDAQ:VAXX) announced its quarterly earnings data on Thursday, November, 10th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.16) by $0.01. When did Vaxxinity IPO? (VAXX) raised $90 million in an initial public offering on Thursday, November 11th 2021. The company issued 6,000,000 shares at $14.00-$16.00 per share. What is Vaxxinity's stock symbol? Vaxxinity trades on the NASDAQ under the ticker symbol "VAXX." How do I buy shares of Vaxxinity? Shares of VAXX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Vaxxinity's stock price today? One share of VAXX stock can currently be purchased for approximately $3.58. How much money does Vaxxinity make? Vaxxinity (NASDAQ:VAXX) has a market capitalization of $451.29 million and generates $70,000.00 in revenue each year. The company earns $-137,180,000.00 in net income (profit) each year or ($1.24) on an earnings per share basis. How can I contact Vaxxinity? The official website for the company is www.vaxxinity.com. The company can be reached via phone at 254-244-5739 or via email at ir@vaxxinity.com. This page (NASDAQ:VAXX) was last updated on 1/28/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.